Theratechnologies, Inc. (THTX): Price and Financial Metrics
THTX Price/Volume Stats
| Current price | $1.38 | 52-week high | $4.30 |
| Prev. close | $1.34 | 52-week low | $0.88 |
| Day low | $1.33 | Volume | 18,700 |
| Day high | $1.38 | Avg. volume | 63,374 |
| 50-day MA | $1.43 | Dividend yield | N/A |
| 200-day MA | $1.69 | Market Cap | 33.40M |
THTX Stock Price Chart Interactive Chart >
Theratechnologies, Inc. (THTX) Company Bio
Theratechnologies, Inc. is a specialty pharmaceutical company that discovers and develops therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. The Company's main product is being marketed in the United States for the reduction of excess abdominal fat n HIV-infected patients with lipodystrophy.
Latest THTX News From Around the Web
Below are the latest news stories about THERATECHNOLOGIES INC that investors may wish to consider to help them evaluate THTX as an investment opportunity.
Theratechnologies Announces Renewal of Shelf Prospectus and Filing of Registration StatementTheratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities of all the provinces of Canada and a corresponding shelf registration statement with the United States Securities and Exchange Commission (the "SEC") on Form F-3. |
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading DoseUpdated label means new Trogarzo® patients no longer require initiation of treatment by 30-minute infusionComplete IV push method enables easier and more convenient administration of Trogarzo® for heavily treatment-experienced adults with HIV This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Theratechn |
Theratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation AwardHonor awarded last night recognizes Theratechnologies and Prof. Borhane Annabi for advancing preclinical development of sudocetaxel zendusortide for treatment of triple-negative breast cancerMONTREAL, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSR |
Theratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementThis news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement datedDecember 16, 2021 to its short form base shelf prospectus dated December 14, 2021. MONTREAL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off Thursday with a breakdown of the biggest pre-market stock movers investors will want to watch this morning. |
THTX Price Returns
| 1-mo | 3.76% |
| 3-mo | -13.48% |
| 6-mo | 40.83% |
| 1-year | -61.67% |
| 3-year | -89.94% |
| 5-year | -93.22% |
| YTD | -14.81% |
| 2023 | -54.12% |
| 2022 | -70.86% |
| 2021 | 21.20% |
| 2020 | -24.24% |
| 2019 | -45.90% |
Loading social stream, please wait...